Sun Pharma inks pact with Bayer to sell drug for chronic kidney disease

Sun Pharma has partnered up with Bayer to market Finerenone, a drug for chronic kidney disease, in India. Bayer grants non-exclusive rights to Sun Pharma to distribute Finerenone under the brand name Lyvelsa. Sun Pharma CEO emphasizes commitment to providing innovative medicines to Indian patients.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news